Articlenpj biomedical innovations2025
Artificial intelligence-based triaging of cutaneous melanocytic lesions.
Article in npj biomedical innovations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Melan-Dx: a knowledge-enhanced vision-language framework improves differential diagnosis of melanocytic neoplasm pathology.NPJ digital medicine · 2026Article
- Artificial Intelligence in Histopathological Analysis for Predicting Immunotherapy Response in Cutaneous Melanoma.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathologists are facing an increasing workload due to a growing volume of cases and the need for more comprehensive diagnoses. Aiming to facilitate workload reduction and faster turnaround times, we developed an artificial intelligence (AI) model for triaging cutaneous melanocytic lesions based on whole slide images. The AI model was developed and validated using a retrospective cohort from the University Medical Center Utrecht, the Netherlands. The dataset consisted of 52,202 whole slide images from 27,167 unique specimens, acquired from 20,707 patients. Specimens with only benign common nevi, also known as moles, were assigned to the low complexity category (86.6%). In contrast, specimens with any other melanocytic lesion subtype, including non-common nevi, melanocytomas, and melanomas, were assigned to the high complexity category (13.4%). The dataset was split on patient level into a development set (80%) and test sets (20%) for independent evaluation. Predictive performance was primarily measured using the area under the receiver operating characteristic curve (AUROC) and the area under the precision-recall curve (AUPRC). A simulation experiment was performed to study the effect of implementing AI-based triaging in the clinic. The AI model reached an AUROC of 0.966 (95% CI, 0.960-0.972) and an AUPRC of 0.857 (95% CI, 0.836-0.877) on the in-distribution test set, and an AUROC of 0.899 (95% CI, 0.860-0.934) and an AUPRC of 0.498 (95% CI, 0.360-0.639) on the out-of-distribution test set. In the simulation experiment, using random case assignment as baseline, AI-based triaging prevented an average of 43.9 (95% CI, 36-55) initial examinations of high complexity cases by general pathologists for every 500 cases. In conclusion, the AI model achieved a strong predictive performance in differentiating between cutaneous melanocytic lesions of high and low complexity. The improvement in workflow efficiency due to AI-based triaging could be substantial.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.